Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron Pharmaceuticals

This Is What Whales Are Betting On Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 11 strange trades.

Dow Jones Drops After Market Sell-Off; HP Soars On Warren Buffett Stake

Dow Jones Drops After Market Sell-Off; HP Soars On Warren Buffett Stake

The Dow Jones Industrial Average fell Thursday following two straight days of sharp market sell-offs. HP soared 15% on a Warren Buffett stake.

Investors Business Daily

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 11.29% on an annualized basis producing an average annual return of 18.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $77.02 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Dow Jones Slides After Stock Market Sell-Off As 10-Year Treasury Yield Surges

The Dow Jones Industrial Average slid Wednesday, extending losses from Tuesday's stock market sell-off, as the 10-year Treasury yield surged.

Investors Business Daily

Dow Jones Falls After Stock Market Rally; Elon Musk To Join Twitter Board

The Dow Jones Industrial Average dropped Tuesday. Tesla CEO Elon Musk is set to join Twitter's board of directors.

Investors Business Daily

Dow Jones Futures: Apple Retakes Entry, Tesla Eyes Buy Point And Twitter Soars On Musk Stake

Dow Jones futures were lower ahead of this week's Fed minutes. Apple and Tesla stock made bullish moves, while Twitter soared 27%.

Investors Business Daily

Executives Sell More Than $262M Of 5 Stocks

Although gold futures traded higher on Monday, there were a few notable insider trades.

inkl

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Falls; Tesla Rises Despite 'Exceptionally Difficult Quarter'; Twitter Soars On Musk Stake

Dow Jones Falls; Tesla Rises Despite 'Exceptionally Difficult Quarter'; Twitter Soars On Musk Stake

The Dow Jones Industrial Average fell Monday, as Tesla climbed after the company reported record vehicle deliveries.

Investors Business Daily

Dow Jones Rallies After March Jobs Report Miss; Treasury Yields Surge

Dow Jones Rallies After March Jobs Report Miss; Treasury Yields Surge

The Dow Jones Industrial Average rallied Friday after the March jobs report miss. The 10-year Treasury yield surged.

Investors Business Daily

Dow Jones Falls; Oil Prices Dive As U.S. Eyes Reserve Release

Dow Jones Falls; Oil Prices Dive As U.S. Eyes Reserve Release

The Dow Jones Industrial Average fell Thursday. Oil prices dived on news that the Biden administration is planning to tap U.S. oil reserves.

Investors Business Daily

Overview Of Value Stocks In The Healthcare Sector

Overview Of Value Stocks In The Healthcare Sector

What are Value Stocks?

IBD 50 Stocks To Watch: This Pharma Stock Is Building A New Base

IBD 50 Stocks To Watch: This Pharma Stock Is Building A New Base

Regeneron Pharmaceuticals rejoins the IBD 50 hot stocks to watch as it builds a new base and could break out.

Investors Business Daily

Recap: Regeneron Pharmaceuticals Q4 Earnings

Recap: Regeneron Pharmaceuticals Q4 Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Earnings Preview For Regeneron Pharmaceuticals

Earnings Preview For Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Regeneron Pharmaceuticals will likely report an Earnings Per Share (EPS) of $18.11.

Get all your
news in one place.

100’s of premium titles.
One news app.

Analyst Ratings For Regeneron Pharmaceuticals

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

American Express

IBD MarketSmith

IBD Leaderboard

Arista Networks

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

235,915 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play